These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 17660651)
1. Effect of intravenous iron saccharate on the requirements of erythropoietin in hemodialysis patients. Shaheen FA; Souqiyyeh MZ; Akeel N Saudi J Kidney Dis Transpl; 2002; 13(2):131-40. PubMed ID: 17660651 [TBL] [Abstract][Full Text] [Related]
2. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H; Wang SX Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498 [TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of maintenance intravenous iron saccharate in hemodialysis patients. Al-Mueilo SH Saudi J Kidney Dis Transpl; 2005; 16(2):146-53. PubMed ID: 18202490 [TBL] [Abstract][Full Text] [Related]
4. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241 [TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N; Osman-Malik Y; Frinak S; Besarab A Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942 [TBL] [Abstract][Full Text] [Related]
6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
7. Intravenous Iron Saccharate in Hemodialysis Patients Receiving r-HuEPO. Al-Momen AK; Huraib SO; Mitwalli AH; Al-Wakeel J; Al-Yamani MJ; Abu-Aisha H; Said R Saudi J Kidney Dis Transpl; 1994; 5(2):168-72. PubMed ID: 18583828 [TBL] [Abstract][Full Text] [Related]
8. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416 [TBL] [Abstract][Full Text] [Related]
9. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926 [TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients. Tarng DC; Hung SC; Huang TP J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999 [TBL] [Abstract][Full Text] [Related]
11. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis]. Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Geisser P; Rumyantsev V Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929 [TBL] [Abstract][Full Text] [Related]
13. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Bailie GR Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930 [TBL] [Abstract][Full Text] [Related]
15. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients. Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121 [TBL] [Abstract][Full Text] [Related]
16. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein]. Martone M; Zanchi R; Panzetta G G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284 [TBL] [Abstract][Full Text] [Related]
17. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Chen YC; Hung SC; Tarng DC Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299 [TBL] [Abstract][Full Text] [Related]
18. [Hematological and iron parameters to predict mortality in ESRD]. Cantaro S; Piva E G Ital Nefrol; 2005; 22 Suppl 31():S135-9. PubMed ID: 15786388 [TBL] [Abstract][Full Text] [Related]
19. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Saltissi D; Sauvage D; Westhuyzen J Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286 [TBL] [Abstract][Full Text] [Related]
20. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study]. Li H; Wang SX Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]